research
past
year
implic
dipeptidyl
peptidas
dpp
famili
variou
physiolog
process
patholog
immun
system
usual
four
prolylspecif
peptidas
consid
dppiv
ec
fibroblast
activ
protein
fap
ec
recent
discov
ec
howev
due
similar
substrat
specif
structur
homolog
relev
consid
broader
famili
also
includ
prolyl
oligopeptidas
prep
ec
dipeptidyl
peptidas
ii
dppii
ec
prolyl
carboxypeptidas
prcp
ec
first
dppii
prcp
share
hydrolas
fold
dpp
catalyt
triad
complet
conserv
enzym
moreov
dppii
cleav
sever
dppiv
substrat
vitro
convers
due
substrat
prefer
tripeptid
dppii
could
actual
consid
prolyl
carboxytripeptidas
emphas
similar
prcp
anoth
argument
consid
broader
famili
stem
fact
function
studi
role
peptidas
reli
heavili
use
enzym
inhibitor
mani
inhibitor
use
earlier
studi
known
inhibit
one
famili
member
exampl
earli
studi
dppiv
use
inhibitor
know
also
inhibit
dppii
fap
andor
prep
due
sequenti
andor
structur
similar
eg
ref
prcp
known
inhibit
zproprolin
higher
concentr
often
use
function
studi
prep
eg
ref
tabl
summar
commonli
use
dpp
inhibitor
select
compar
dppiv
view
aforement
reason
sake
simplic
use
dpp
famili
blanket
term
includ
dppii
prcp
prep
even
though
strictli
speak
dpp
figur
provid
gener
overview
broadli
defin
dpp
famili
role
variou
famili
member
certain
aspect
immun
system
immun
dysfunct
review
past
eg
ref
review
provid
comprehens
discuss
updat
role
dppiv
dppii
fap
prep
prcp
immun
system
inflammatori
diseas
highlight
role
enzym
atherosclerosi
condit
lie
frontier
inflamm
cardiovascular
diseas
dpp
famili
encompass
possibl
therapeut
target
prevent
treatment
diseas
prototyp
dpp
dppiv
often
medic
jargon
cleav
ntermin
dipeptid
peptid
pro
ala
penultim
posit
local
solubl
enzym
bodi
fluid
anchor
plasma
membran
cell
provid
necessari
access
cleav
wide
rang
bioactiv
peptid
modifi
biolog
activ
glucagonlik
peptid
glp
glucosedepend
insulinotrop
peptid
gip
substanc
p
neuropeptid
npi
stromal
cellderiv
granulocyt
macrophag
colonystimul
factor
gmcsf
highmobl
group
box
identifi
physiolog
substrat
other
rant
propos
base
vitro
experi
eg
ref
dppiv
also
perform
mani
physiolog
function
interact
protein
collagen
fibronectin
adenosin
deaminas
ada
growth
factor
ii
receptor
discuss
detail
dipeptidyl
peptidas
iv
well
known
role
glucos
homeostasi
becom
valid
therapeut
target
treatment
type
diabet
dppiv
inhibitor
reduc
rate
inactiv
box
also
shown
involv
cancer
biolog
role
dpp
famili
cancer
address
sever
review
final
dppiv
recent
come
back
center
attent
receptor
mer
coronaviru
fibroblast
activ
protein
also
known
sepras
present
type
ii
transmembran
protein
shed
plasma
proteas
latter
case
also
known
antiplasmincleav
enzym
convert
activ
form
suppress
fibrinolysi
known
dppiv
substrat
later
found
cleav
vitro
fap
well
though
physiolog
relev
remain
unclear
unlik
dppiv
fap
also
possess
gelatinas
activ
enabl
fap
degrad
protein
extracellular
matrix
particular
interest
regard
involv
number
patholog
process
fap
highli
induc
inflamm
activ
hepat
stellat
cell
liver
cirrhosi
strongli
express
mesenchym
cell
remodel
tissu
fap
also
key
regul
tumor
growth
metastasi
process
requir
degrad
extracellular
matrix
fap
involv
patholog
like
associ
gelatinas
activ
role
cancer
biolog
review
interest
note
far
clinic
trial
talabostat
shown
minim
clinic
benefit
treatment
metastat
colorect
cancer
advanc
nonsmal
cell
lung
cancer
stage
iv
melanoma
mention
howev
talabostat
broadrang
inhibitor
also
target
dppiv
dipeptidyl
peptidas
show
dppivlik
activ
share
highsequ
similar
aa
similar
aa
ident
cytoplasm
enzym
sever
isoform
matter
debat
whether
express
protein
cell
whether
activ
interestingli
ntermin
extens
longer
variant
contain
nuclear
local
signal
inde
form
local
nucleu
shown
cleav
number
dppiv
chemokin
substrat
vitro
anoth
dppiv
substrat
npi
indirectli
shown
substrat
well
effort
made
find
intracellular
substrat
use
peptidom
approach
far
hard
attribut
physiolog
relev
possibl
substrat
beyond
role
intracellular
peptid
turnov
physiolog
function
still
properli
understood
mainli
lack
avail
knockout
anim
specif
inhibitor
substrat
hamper
progress
mous
model
establish
target
inactiv
enzymat
activ
homozyg
neonat
die
within
h
birth
despit
limit
indic
toward
role
surfac
use
immunohistochemistri
found
associ
spermatozoid
spermatid
short
mrna
predominantli
express
test
suggest
role
spermatogenesi
male
fertil
recent
work
found
alloster
activ
wherea
small
peptid
correspond
interact
surfac
noncompetit
inhibitor
genomewid
associ
studi
link
idiopath
pulmonari
fibrosi
final
number
studi
shown
role
apoptosi
two
studi
show
overexpress
enhanc
induc
apoptosi
impair
cell
adhes
migrat
convers
inhibit
tumor
cell
decreas
number
viabl
cell
decreas
cleavag
proapoptot
npi
macrophag
inhibit
caus
margin
yet
signific
increas
apoptosi
independ
npi
cleavag
interestingli
vildagliptin
dppiv
inhibitor
alreadi
market
treat
type
diabet
poorer
select
toward
shown
enhanc
parthenolid
antileukem
activ
inhibit
dppiv
prolyl
carboxypeptidas
also
call
angiotensinas
c
lysosom
prox
carboxypeptidas
lysosom
carboxypeptidas
share
strong
sequenc
homolog
likewis
lysosom
dppii
prcp
preferenti
cleav
ctermin
amino
acid
ala
pro
penultim
posit
dppii
target
ntermin
xpro
xala
dipeptid
addit
structur
similar
prcp
dppii
partial
overlap
substrat
specif
due
dppii
prefer
tripeptid
substrat
perhap
surprisingli
glypropna
alapropna
two
typic
synthet
dpp
substrat
actual
use
perform
prcp
activ
measur
prolyl
carboxypeptidas
particularli
known
one
key
enzym
system
ra
inactiv
vasoact
peptid
angiotensin
ii
angiotensin
iii
cleav
ctermin
phe
hormon
anorexigen
neuromodul
inactiv
prcp
impli
role
bodi
weight
control
base
involv
prcp
convers
peptid
hormon
enzym
also
associ
diseas
hypertens
diabet
mellitu
obes
inflamm
cardiovascular
dysfunct
dipeptidyl
peptidas
ii
known
natur
substrat
dppiv
substrat
substanc
p
shown
cleav
dppii
vitro
much
less
effici
cast
doubt
physiolog
relev
shown
inhibit
silenc
dppii
caus
apoptosi
quiescent
lymphocyt
hand
highli
specif
dppii
inhibitor
induc
apoptosi
autophagi
necrosi
human
leukocyt
studi
specif
look
quiescent
cell
lymphocyt
final
chang
dppii
activ
level
observ
number
patholog
neurodegen
disord
myopathi
cancer
gastrointestin
disord
prolyl
oligopeptidas
oligopeptidas
endopeptidas
activ
shown
local
cytoplasm
given
abil
inactiv
sever
neuropeptid
vitro
limit
proteolysi
involv
vivo
gener
immunoact
peptid
nacetylprolylglycylprolin
nacetylserylaspartyllysylprolin
presenc
plasma
like
also
extracellular
role
initi
interest
prep
deriv
posit
effect
prep
inhibitor
scopolamineinduc
amnesia
rat
prep
inhibit
also
found
promot
neuron
surviv
neurit
outgrowth
cerebellar
granul
cell
howev
recent
studi
mice
show
lack
prep
vivo
caus
reduct
synapt
spine
densiti
hippocamp
region
along
reduc
longterm
potenti
memori
function
mani
prep
function
mediat
interact
protein
prep
known
interact
gadph
studi
interact
review
ref
prep
shown
coloc
cell
model
stress
substantia
nigra
postmortem
parkinson
diseas
brain
vitro
aggreg
rate
increas
presenc
high
concentr
prep
abolish
activ
site
inhibitor
prep
absent
catalyt
impair
prep
mutant
vivo
prep
inhibit
reduc
aggreg
cellular
anim
model
parkinson
diseas
role
dppiv
monocyt
macrophag
somewhat
contest
wherea
dppiv
presenc
monocyt
macrophag
shown
repeatedli
mice
rat
express
human
monocyt
macrophag
less
obviou
figur
show
overview
express
dppiv
throughout
immun
system
viscer
obes
dppiv
express
low
peripher
blood
monocyt
macrophag
dendrit
cell
upregul
vitro
differenti
activ
isol
monocyt
macrophag
dendrit
cell
vivo
local
adipos
tissu
interestingli
author
show
macrophag
dendrit
cellassoci
dppiv
like
bind
ada
promot
local
degrad
adenosin
tcell
prolifer
suppressor
therebi
induc
tcell
prolifer
three
studi
also
found
low
dppiv
express
activ
associ
human
monocyt
andor
macrophag
other
investig
dppiv
monocyt
macrophagelik
cell
line
cell
express
found
regul
differenti
macrophagelik
cell
dppiv
inhibitor
alogliptin
affect
erk
activ
secret
cell
howev
studi
employ
alogliptin
concentr
lower
dppiv
therefor
question
whether
observ
effect
mediat
dppiv
hand
prolifer
reduc
presenc
dpp
inhibitor
cell
express
high
level
dppiv
cell
type
express
low
level
dppiv
moreov
inhibitor
caus
former
cell
secret
lower
amount
higher
amount
could
inhibit
mere
increas
halflif
dppiv
implic
degrad
cell
cell
dppiv
inhibitor
alogliptin
sitagliptin
reduc
cell
chemotact
potenti
dppiv
inhibitor
sitagliptin
also
reduc
express
increas
express
cell
effect
block
pma
differenti
importantli
cell
line
deriv
differ
type
myeloid
leukemia
known
dppiv
express
often
dysregul
cancer
physiolog
relev
find
remain
uncertain
fap
shown
tumorassoci
macrophag
human
breast
cancer
dipeptidyl
peptidas
activ
found
human
monocyt
cell
found
associ
activ
microgliamacrophag
rat
model
cerebr
ischemia
abundantli
present
macrophagerich
region
atherosclerot
plaqu
interestingli
upregul
vitro
monocytetomacrophag
differenti
moreov
inhibit
rna
silenc
attenu
proinflammatori
macrophag
activ
rat
dppii
express
tissueresid
macrophag
human
show
dppii
activ
monocyt
well
cell
human
blood
deriv
alveolar
macrophag
show
highprcp
activ
interestingli
mous
vivo
angiogenesi
assay
macrophag
infiltr
wound
increas
mice
prcp
delet
prolyl
oligopeptidas
activ
shown
mous
rat
periton
macrophag
rat
pulmonari
macrophag
activ
mous
periton
macrophag
increas
thioglycol
ellicit
addit
prep
identifi
neurotox
compon
supernat
activ
cell
monocytelik
cell
appar
cell
secret
prep
upon
activ
lp
partli
supernat
toxic
neuroblastoma
cell
shown
use
prepspecif
inhibitor
prep
mode
action
remain
unclear
recent
studi
show
dppiv
act
chemorepel
human
murin
neutrophil
ad
recombin
dppiv
purifi
human
neutrophil
insal
chamber
caus
neutrophil
migrat
away
higher
concentr
dppiv
effect
block
dppiv
inhibitor
mean
effect
mediat
dppiv
enzymat
activ
although
candid
substrat
obviou
moreov
mous
model
acut
respiratori
distress
syndrom
oropharyng
aspir
dppiv
prevent
accumul
neutrophil
lung
contrast
prep
involv
gener
prolylglycylprolin
collagen
fragment
effici
neutrophil
chemoattract
human
peripher
blood
neutrophil
contain
prep
activ
capabl
gener
prolylglycylprolin
lpsactiv
allud
selfsustain
pathway
neutrophil
inflamm
prcp
also
abundantli
express
human
neutrophil
recruit
eosinophil
affect
dppiv
activ
also
known
eotaxin
dppiv
substrat
cleavag
dppiv
prevent
activ
receptor
rat
shown
administr
result
eosinophil
recruit
recruit
significantli
effect
dppivdefici
mutant
final
dppii
activ
report
granul
mast
cell
sever
public
releas
periton
mast
cell
upon
degranul
appar
inhibit
histamin
concentr
present
granul
mast
cell
dipeptidyl
peptidas
present
low
amount
freshli
isol
human
nk
cell
express
upregul
small
subpopul
stimul
studi
also
shown
dppiv
inhibit
suppress
dna
synthesi
cell
cycl
progress
nk
cell
effect
may
mediat
inhibitor
use
studi
known
also
inhibit
activ
anoth
studi
show
dppiv
actual
express
small
subpopul
peripher
nk
cell
natur
cytotox
nk
cell
influenc
presenc
absenc
dppiv
cell
surfac
howev
dppivneg
nk
cell
show
significantli
less
lysi
dppivposit
nk
cell
interestingli
nk
cytolyt
function
tumor
cell
diminish
dppivdefici
rat
model
lung
metastasi
figur
show
overview
publish
data
dpp
famili
innat
immun
system
freshli
isol
b
cell
express
dppiv
fraction
grow
significantli
upon
pokewe
mitogen
pwm
aureu
protein
stimul
similar
nk
cell
dppiv
inhibitor
significantli
suppress
dna
synthesi
blymphocyt
inhibitor
known
also
inhibit
mous
spleenderiv
blymphocyt
express
low
amount
dppiv
mrna
mrna
hand
express
much
greater
level
cell
upregul
raji
cell
blymphocytelik
cell
line
pwm
lp
stimul
mitomycin
c
treatment
downregul
dtt
treatment
also
shown
immunohistochem
human
lymph
follicular
lymphocyt
dppii
activ
also
shown
human
blymphocyt
dipeptidyl
peptidas
iv
origin
describ
surfac
marker
tlymphocyt
case
better
known
later
specif
subset
memori
cell
cell
respond
maxim
recal
antigen
tetanu
toxoid
induc
bcell
igg
synthesi
inde
surfac
express
augment
along
antigen
sensit
particular
tcell
clone
tcell
belong
earli
effector
memori
tcell
subset
also
marker
tcell
activ
express
tcell
correl
respons
stimuli
typic
induc
phenotyp
tend
induc
express
addit
cell
capabl
transendotheli
migrat
vitro
character
bright
express
seem
actual
involv
tcell
adhes
endotheli
cell
fibroblast
recent
shown
cell
show
high
express
mean
fluoresc
intens
cell
almost
twice
high
cell
therefor
author
studi
suggest
marker
cell
convers
propos
neg
marker
select
treg
cell
due
lowsurfac
express
cell
also
costimulatori
molecul
tcell
activ
crosslink
along
stimul
tcell
activ
prolifer
also
directli
activ
tcell
altern
activ
pathway
requir
presenc
complex
costimul
phosphoryl
intern
latter
mediat
part
interact
local
lipid
raft
might
interact
requir
tcr
signal
facilit
coloc
molecul
tcr
signal
molecul
number
candid
bind
partner
costimul
propos
ada
known
bind
partner
even
though
ada
bind
seem
essenti
immun
function
human
nanomolar
affin
interact
probabl
reflect
import
inde
associ
free
ada
ada
present
adaanchor
protein
dendrit
cell
seem
costimul
tcell
bind
hand
shown
solubl
dppiv
enhanc
tcell
prolifer
independ
enzym
activ
adabind
capabl
interestingli
interact
inhibit
extern
envelop
protein
requir
interact
fact
evid
suggest
physic
associ
peripher
blood
lymphocyt
fibronectin
anoth
known
bind
partner
involv
tcell
costimul
final
interact
monocyt
interact
caus
upregul
cell
potenti
antigenspecif
tcell
activ
studi
seem
find
need
dppiv
enzymat
activ
succes
costimul
evidenc
use
inhibitor
catalyt
impair
dppiv
mutant
dipeptidyl
peptidas
present
baboon
spleen
interfollicular
tlymphocyt
jurkat
cell
upregul
latter
pwm
lp
pha
stimul
activ
pwmstimul
tcell
suppress
inhibit
moreov
dna
synthesi
tcell
prolifer
reduc
well
product
due
induct
secret
inhibit
also
upregul
downregul
dppiv
express
observ
might
physiolog
relev
endogen
inhibitor
dpp
known
similar
effect
cellbas
experi
synthet
inhibitor
dipeptidyl
peptidas
ii
activ
higher
tlymphocyt
blymphocyt
absenc
dppii
steer
tlymphocyt
toward
phenotyp
tlymphocyt
dppii
ko
mice
hyperprolifer
secret
crosslink
vivo
prime
vitro
antigenspecif
restimul
prep
activ
also
shown
mous
tlymphocyt
activ
significantli
higher
immatur
doubleposit
thymocyt
compar
matur
singleposit
thymocyt
peripher
tcell
tcell
stimul
con
follow
show
timedepend
increas
prep
activ
pretreat
cell
prep
inhibitor
render
resist
activationinduc
cell
death
figur
show
overview
vitro
data
dpp
involv
primari
human
cell
activ
dpp
famili
report
dysregul
even
involv
number
inflammatori
disord
express
level
number
famili
member
modul
rheumatoid
arthriti
wherea
densiti
peripher
cell
increas
patient
low
synovi
fluid
cell
dppiv
activ
plasma
serum
synovi
fluid
patient
also
found
decreas
similar
result
sever
rat
model
arthriti
interestingli
rat
resist
induct
arthriti
show
higher
plasma
dppiv
level
contrast
dppii
prep
activ
increas
serum
synovi
fluid
arthriti
patient
likewis
fap
immunoreact
much
higher
fibroblastlik
synoviocyt
rheumatoid
arthriti
patient
compar
osteoarthr
control
dppiv
involv
rheumatoid
arthriti
studi
remain
unclear
one
hand
inhibit
suppress
develop
arthriti
rat
note
howev
effect
mediat
dpp
hard
exclud
inhibitor
develop
discov
hand
induc
arthriti
sever
dppivdefici
mice
may
due
increas
level
circul
dppiv
substrat
shown
involv
rheumatoid
arthriti
sever
case
report
patient
seem
suggest
link
develop
rheumatoid
arthriti
use
dppiv
inhibitor
prcp
also
associ
rheumatoid
arthriti
activ
shown
synovi
fluid
isol
arthrit
joint
inflammatori
bowel
diseas
show
distinct
express
pattern
dpp
famili
dppiv
serum
plasma
activ
seem
lower
patient
wherea
increas
circul
cell
higher
surfac
express
fap
heavili
express
myofibroblast
submucosa
strictur
crohn
diseas
upregul
stimul
mous
model
colon
dppii
mrna
dppii
activ
increas
colon
activ
increas
significantli
mice
also
dppiv
knockout
mous
model
inhibit
abrog
dppiv
seem
least
partial
amelior
symptom
possibl
increas
circul
impair
neutrophil
recruit
maintain
treg
popul
benefici
effect
may
mediat
part
dpp
addit
effect
found
dppiv
ko
dpp
inhibitor
recent
studi
suggest
amelior
effect
dpp
inhibitor
like
mediat
protect
dpp
famili
also
studi
neuroinflamm
ischemiainduc
neuroinflamm
rat
prompt
distinct
express
activ
pattern
dpp
day
follow
ischemia
brain
rat
undergo
complex
reorgan
dpp
express
chang
mrna
protein
activ
level
dppii
cortic
neuron
microglia
macrophag
similarli
prep
seem
associ
astrocyt
microglia
lesion
inflam
brain
rat
dppiv
prep
also
may
involv
multipl
sclerosi
cell
found
correl
diseas
score
solubl
dppiv
level
elev
cerebrospin
fluid
patient
plasma
prep
activ
hand
lower
patient
primari
progress
multipl
sclerosi
clinic
isol
syndrom
interestingli
prep
inhibit
seem
aggrav
symptom
mous
model
multipl
sclerosi
system
lupu
erythematosu
dpp
also
seem
dysregul
mous
model
dppii
prep
activ
increas
plasma
spleen
kidney
liver
wherea
dppiv
activ
decreas
human
patient
also
show
elev
dppii
reduc
dppiv
activ
serum
along
reduc
number
cell
interestingli
serum
dppiv
level
invers
correl
diseas
score
fap
immunoreact
decreas
synovium
lupu
patient
final
dppiv
studi
psoriasi
immunemedi
chronic
inflammatori
disord
primari
involv
skin
joint
mrna
protein
level
activ
higher
psoriat
skin
sampl
contrast
serum
dppiv
level
activ
seem
lower
patient
accompani
reduct
peripher
cell
two
case
report
suggest
link
use
dppiv
inhibitor
sitagliptin
psoriasi
one
woman
develop
psoriaform
erupt
day
start
sitagliptin
treatment
anoth
patient
psoriat
lesion
gradual
diminish
effect
gone
month
start
sitagliptin
treatment
dipeptidyl
peptidas
iv
recent
receiv
much
attent
potenti
therapeut
target
treatment
atherosclerosi
box
surpris
consid
current
use
dppiv
inhibitor
treatment
fact
associ
higher
risk
atherosclerosi
mous
model
atherosclerosi
dppiv
inhibit
gener
reduc
plaqu
area
monocyt
macrophag
plaqu
infiltr
reduct
number
plaqu
lesion
smooth
muscl
cell
content
also
observ
well
lower
plaqu
higher
plaqu
collagen
level
suggest
increas
plaqu
stabil
one
studi
report
effect
dppiv
inhibit
atherosclerot
plaqu
diabet
mice
recent
terasaki
et
al
found
similar
effect
nondiabet
diabet
mice
like
differ
explain
fact
differ
dppiv
inhibitor
employ
effect
dppiv
atherogenesi
similar
observ
mice
reproduc
mice
human
atherosclerot
plaqu
dppiv
immunoreact
could
found
endothelium
neovessel
recent
found
dppiv
activ
may
predictor
onset
atherosclerosi
otherwis
healthi
chines
individu
anoth
prospect
studi
investig
influenc
vildagliptin
sitagliptin
treatment
intimamedia
thick
surrog
marker
atherosclerosi
studi
found
treatment
vildagliptin
sitagliptin
reduc
intimamedia
thick
suggest
dppiv
inhibit
might
benefici
atherosclerosi
human
well
moreov
treatment
patient
treat
alogliptin
month
saw
signific
decreas
circul
atherogen
lipid
suggest
dppiv
inhibitor
antiatherogen
effect
mainli
mediat
decreas
monocyt
infiltr
dppiv
inhibitor
suppress
monocyt
activ
chemotaxi
vitro
dppiv
inhibit
also
reduc
vitro
foam
cell
format
exud
periton
macrophag
mice
moreov
solubl
dppiv
stimul
vitro
prolifer
smooth
muscl
cell
reduc
addit
dppiv
inhibitor
final
activ
circul
level
augment
improv
endotheli
dysfunct
probabl
dppiv
inhibit
improv
atherosclerosi
combin
mechan
inde
incretin
antagonist
partial
attenu
antiatherogen
effect
dppiv
inhibit
suggest
mechan
beyond
incretin
preserv
play
interestingli
cell
adhes
abrog
antibodi
vitro
ldl
seem
induc
express
lead
smooth
muscl
cell
prolifer
inhibit
cell
apoptosi
dppiv
substrat
lose
biolog
activ
cleavag
dppiv
inhibit
seem
improv
atherosclerosi
wherea
intact
appear
deletori
could
argu
cleavag
dppiv
play
major
role
atherosclerosi
dipeptidyl
peptidas
found
abundantli
present
macrophagerich
region
human
atherosclerot
plaqu
consid
role
macrophag
activ
might
potenti
involv
atherogenesi
fap
express
enhanc
type
human
atheromata
found
smooth
muscl
cell
express
correl
macrophag
burden
probabl
due
fact
upregul
fap
smooth
muscl
cell
vitro
mainli
associ
collagenpoor
region
digest
type
collagen
gelatin
vitro
fap
probabl
contribut
plaqu
instabl
interestingli
mani
studi
review
show
potenti
target
dpp
famili
member
treatment
atherosclerosi
see
figur
fap
inhibit
might
reduc
plaqu
instabl
decreas
collagen
breakdown
inhibit
like
attenu
macrophag
activ
reduc
local
inflammatori
cascad
dppiv
inhibit
may
decreas
monocyt
infiltr
foam
cell
format
improv
endotheli
dysfunct
reduc
smooth
muscl
cell
prolifer
final
prep
inhibit
might
reduc
neutrophil
infiltr
prevent
endotheli
dysfunct
monocyt
infiltr
show
possibl
reposit
dppiv
inhibitor
current
use
treat
type
diabet
well
potenti
target
member
dpp
famili
caution
taken
interpret
result
literatur
data
base
dpp
inhibitor
especi
older
studi
known
experiment
condit
use
mani
inhibitor
specif
one
particular
famili
member
report
find
howev
remain
interest
review
shown
extens
involv
member
dpp
famili
immun
system
clear
enzym
hold
great
potenti
target
treatment
certain
inflammatori
disord
particularli
possibl
target
dpp
famili
member
prevent
treatment
atherosclerosi
warrant
investig
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
